Dual-Targeting Dual-Action Platinum(IV) Platform for Enhanced Anticancer Activity and Reduced Nephrotoxicity.

A novel and highly efficient dual-targeting platform was designed to ensure targeted in vivo delivery of dual-action PtIV prodrugs. The dual targeting was established by liposomal encapsulation of PtIV complexes, thereby utilizing the enhanced permeability and retention (EPR) effect as the first stage of targeting to attain a high accumulation of the drug-loaded liposomes in the tumor. After the release of the PtIV prodrug inside cancer cells, a second stage of targeting directed a portion of the PtIV prodrugs to the mitochondria. Upon intracellular reduction, these PtIV prodrugs released two bioactive molecules, acting both on the mitochondrial and on the nuclear DNA. Our PtIV system showed excellent activity in vitro and in vivo, characterized by a cytotoxicity in a low micromolar range and complete tumor remission, respectively. Notably, marked in vivo activity was accompanied by reduced kidney toxicity, highlighting the unique therapeutic potential of our novel dual-targeting dual-action platform.

[1]  Zijian Guo,et al.  Impact of Mitochondrion-Targeting Group on the Reactivity and Cytostatic Pathway of Platinum(IV) Complexes. , 2018, Inorganic chemistry.

[2]  V. Gandin,et al.  Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance , 2018, Chemical science.

[3]  V. Gandin,et al.  A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. , 2017, Angewandte Chemie.

[4]  P. Stacpoole,et al.  Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. , 2017, Pharmacology & therapeutics.

[5]  P. Tummala,et al.  Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties. , 2016, Journal of the American Society of Nephrology : JASN.

[6]  V. Brabec,et al.  Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d , 2016, Chemical science.

[7]  V. Pichler,et al.  Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines. , 2015, Metallomics : integrated biometal science.

[8]  F. Sánchez-Juanes,et al.  Sub-nephrotoxic cisplatin sensitizes rats to acute renal failure and increases urinary excretion of fumarylacetoacetase. , 2015, Toxicology letters.

[9]  R. Ferriero,et al.  Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate , 2015, Journal of Inherited Metabolic Disease.

[10]  S. Dhar,et al.  Detouring of cisplatin to access mitochondrial genome for overcoming resistance , 2014, Proceedings of the National Academy of Sciences.

[11]  S. Dhar,et al.  Mito-DCA: A Mitochondria Targeted Molecular Scaffold for Efficacious Delivery of Metabolic Modulator Dichloroacetate , 2014, ACS chemical biology.

[12]  E. Michelakis,et al.  Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology , 2013, Front. Oncol..

[13]  M. Zeviani,et al.  Phenylbutyrate Therapy for Pyruvate Dehydrogenase Complex Deficiency and Lactic Acidosis , 2013, Science Translational Medicine.

[14]  S. Dhar,et al.  Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics , 2012, Proceedings of the National Academy of Sciences.

[15]  Tim Rappon,et al.  Overexpression of Pyruvate Dehydrogenase Kinase 1 and Lactate Dehydrogenase A in Nerve Cells Confers Resistance to Amyloid β and Other Toxins by Decreasing Mitochondrial Respiration and Reactive Oxygen Species Production* , 2012, The Journal of Biological Chemistry.

[16]  Q. Lu,et al.  Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. , 2011, International journal of oncology.

[17]  K. Geissler,et al.  In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[18]  D. Newton,et al.  Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC , 2010, International journal of cancer.

[19]  G. Ramesh,et al.  Mechanisms of Cisplatin Nephrotoxicity , 2010, Toxins.

[20]  S. Lippard,et al.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate , 2009, Proceedings of the National Academy of Sciences.

[21]  K. Kirito,et al.  HIF-1 prevents the overproduction of mitochondrial ROS after cytokine stimulation through induction of PDK-1 , 2009, Cell cycle.

[22]  H. Pan,et al.  Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death , 2008, Journal of Pharmacology and Experimental Therapeutics.

[23]  J. Mackey,et al.  Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer , 2008, British Journal of Cancer.

[24]  G. Ramesh,et al.  Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. , 2007, Kidney international.

[25]  S. Linder,et al.  Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA , 2007, International journal of cancer.

[26]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[27]  M. Newman,et al.  Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice , 1999, Cancer Chemotherapy and Pharmacology.

[28]  M. D’Incalci,et al.  Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti‐cancer agents , 1996, International journal of cancer.